Table 2.
Clinical characteristics of the 52 enrolled patients
| Variable | All patients (n = 52) | NAC (n = 20) | Non-NAC (n = 32) | P |
|---|---|---|---|---|
| Age (years) | 0.350 | |||
| < 65 | 35 (67.3) | 15 (75.0) | 20 (62.5) | |
| 65 | 17 (22.7) | 5 (25.0) | 12 (37.5) | |
| Gender | 0.508 | |||
| Male | 29 (55.8) | 10 (50.0) | 19 (59.4) | |
| Female | 23 (44.2) | 10 (50.0) | 13 (40.6) | |
| Body mass index (kg/m2) | 22.5 ± 3.5 | 22.8 ± 3.3 | 22.4 ± 3.6 | 0.542 |
| Preoperative CEA level (ng/ml) | 0.744 | |||
| < 5 | 17 (32.7) | 6 (30.0) | 11 (34.4) | |
| ≥ 5 | 35 (67.3) | 14 (70.0) | 21 (65.6) | |
| Comorbidity | 14 (26.9) | 4 (20.0) | 10 (31.3) | 0.374 |
| Tumour location | 0.636 | |||
| Colon | 42 (80.8) | 15 (75.0) | 27 (84.4) | |
| Rectum | 10 (19.2) | 5 (25.0) | 5 (15.6) | |
| Histology | 0.289 | |||
| Adenocarcinoma | 29 (55.8) | 13 (65.0) | 16 (50.0) | |
| Mucinous/signet-ring | 23 (44.2) | 7 (35.0) | 16 (50.0) | |
| T stage | 0.287 | |||
| T3 | 6 (11.5) | 4 (20.0) | 2 (6.3) | |
| T4 | 46 (88.5) | 16 (80.0) | 30 (93.7) | |
| N stage | 0.506 | |||
| N0 | 8 (15.4) | 3 (15.0) | 5 (15.6) | |
| N1 | 16 (30.8) | 8 (40.0) | 8 (25.0) | |
| N2 | 28 (53.8) | 9 (45.0) | 19 (59.4) | |
| PCI score | 0.031 | |||
| < 12 | 32 (61.5) | 16 (80.0) | 16 (50.0) | |
| ≥ 12 | 20 (38.5) | 4 (20.0) | 16 (50.0) | |
| PCI score | 11.9 ± 5.6 | 9.8 ± 4.7 | 13.7 ± 6.4 | 0.006 |
| Liver metastases | 9 (17.3) | 4 (20.0) | 5 (15.6) | 0.977 |
| Ascites | 22 (42.3) | 8 (40.0) | 14 (43.8) | 0.790 |
| HIPEC regimen | 0.930 | |||
| Lobaplatin+oxaliplatin+raltitrexed | 23 (44.2) | 9 (45.0) | 14 (43.8) | |
| Oxaliplatin+faltitrexed | 29 (55.8) | 11 (55.0) | 18 (56.2) | |
| CC score | 0.018 | |||
| 0–1 | 31 (59.6) | 16 (80.0) | 15 (46.9) | |
| 2–3 | 21 (40.4) | 4 (20.0) | 17 (53.1) | |
| Adjuvant chemotherapy | 0.738 | |||
| Yes | 44 (84.6) | 16 (80.0) | 28 (87.5) | |
| No | 8 (15.4) | 4 (20.0) | 4 (12.5) |
PCI peritoneal carcinomatosis index, CC cytoreduction score